TITLE

Review: Incretin therapy improves glycemic control more than placebo in patients with type 2 diabetes

PUB. DATE
January 2008
SOURCE
ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p3
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a clinical study that evaluates the efficacy of incretin for glycemic control in adults with non-insulin-dependent diabetes. A randomized-controlled trial showed changes in patients' glycated hemoglobin levels, weight and hypoglycemia. It is concluded that the incretin therapy is more effective than placebo in controlling glycemic level, glucagon-like peptide (GLP-1) are associated with weight loss and dipeptidyl peptidase (DDP4) inhibitors are linked with weight gain.
ACCESSION #
28694420

 

Related Articles

  • Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1. Riddle, Matthew C.; Drucker, Daniel J. // Diabetes Care;Feb2006, Vol. 29 Issue 2, p435 

    Discusses a study which summarized several limitations in the treatment of type 2 diabetes and describes the mechanisms of action and clinical data obtained with amylin and glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase IV inhibitors for the treatment of diabetes. Barriers to...

  • COMMENTARY: Review: Incretin therapy improves glycemic control more than placebo in patients with type 2 diabetes. Vella, Adrian // ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p3 

    The author comments on the efficacy of incretin therapy for glycemic control in non-insulin-dependent diabetics. He pointed out that the glucagon-like peptide 1 (GLP1) is associated with a significant incidence of gastrointestinal adverse effects and dipeptidyl peptidase 4 (DDP4) inhibitors are...

  • Glucagon-like peptide agonists. Gadsby, Roger // Practice Nurse;4/9/2010, Vol. 39 Issue 7, p30 

    The article discusses glucagon-like peptide 1 (GLP-1) and its potential role in the treatment of type 2 diabetes. The levels of GLP-1 in people with diabetes are reduced in response to a meal and it is easily broken down by the enzyme dipeptidyl peptidase-4 (DPP-4). Clinical tests reveal that...

  • A gut-heart connection in cardiometabolic regulation. Buglioni, Alessia; Burnett, John C // Nature Medicine;May2013, Vol. 19 Issue 5, p534 

    The article offers information on the study of Kim and colleagues which examines the link between glucagon-like peptide-1 (GLP-1) release from the cardiac hormone atrial natriuretic peptide and gut. It states that glycemia in patients with type 2 diabetes were controlled using GLP-1 receptor...

  • Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. Dave, Darshan J. // Journal of Pharmacology & Pharmacotherapeutics;Oct2011, Vol. 2 Issue 4, p230 

    Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by insulin defi ciency or resistance. Management starts with single oral antidiabetic drug (OAD) but eventually switch over to combination therapy because of progressive ?-cell dysfunction. Hypoglycemia, weight gain, and...

  • A Single Dose of Vildagliptin (VILDA) Decelerates Gastric Emptying. (GE) in Patients with Type 2 Diabetes (T2DM). Woerle, Hans J.; Lindenberger, Thilo; Linke, Rainer; Foley, James E.; Ligueros-Saylan, Monica A.; Zhang, Yiming; He, Yan-Ling; Beglinger, Christoph; Goeke, Burkhard; Schirra, Joerg // Diabetes;Jun2007 Supplement 1, Vol. 56, pA133 

    The dipeptidyl peptidase IV (DPP-4) inhibitor, VILDA increases postprandial (pp) GLP-1 levels 2-4 fold; this is associated with improved islet function and lower glucose (GLU) excursions. Unlike GLP-1 analogs, a multiple dose study with VILDA utilizing 50 mg bid, did not shown the known GLP-I...

  • Glucagon Like Peptides-1 Modulators as Newer Target for Diabetes. Vaidya, H. B.; Goyal, R. K. // Current Drug Targets;Oct2008, Vol. 9 Issue 10, p911 

    Diabetes mellitus (DM) has been recognized as a growing world-wide epidemic by many health advocacy groups including the World Health Organization (WHO). DM affects about 6% of the North American population. A recent report estimated that 8.2% of adult population worldwide has impaired glucose...

  • Long-Acting Glucagon-Like Peptide 1 Receptor Agonists. GARBER, ALAN J. // Diabetes Care;May2011 Supplement 2, Vol. 34, pS279 

    The article examines the efficacy and tolerability of long-acting glucagon-like peptide 1 receptor agonists. The two classes of drugs for treating type 2 diabetes are glucagon-like peptide (GLP)-1 receptor agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors. A definition of incretin effect is...

  • GLP-1 receptor agonist-induced polyarthritis: a case report. Ambrosio, Maria; Monami, Matteo; Sati, Lavinia; Marchionni, Niccolò; Bari, Mauro; Mannucci, Edoardo // Acta Diabetologica;Aug2014, Vol. 51 Issue 4, p673 

    Occasional cases of bilateral, symmetrical, seronegative polyarthritis have been reported in patients treated with dipeptidyl peptidase-4 inhibitors (Crickx et al. in Rheumatol Int, ). We report here a similar case observed during treatment with a GLP-1 receptor agonist. A 42-year-old man with...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics